Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Opinion
Video
Patient Education and Novel Topical Therapies for AD
Key Takeaways
- Age restrictions for PDE4 inhibitors in pediatric atopic dermatitis require careful evaluation of treatment efficacy and safety, addressing parental concerns effectively.
- Roflumilast's approval for multiple dermatologic conditions offers a streamlined treatment approach for patients with overlapping inflammatory issues, potentially simplifying management.
Panelists discuss how age restrictions for PDE4 inhibitors affect treatment decisions for pediatric patients with atopic dermatitis, addressing parental concerns and highlighting the benefits of a single treatment option like roflumilast for managing overlapping inflammatory dermatologic conditions; they also explore current guidelines for corticosteroid use, the potential impact of PDE4 inhibitors on these guidelines, and the future of topical PDE4 inhibitors in dermatology, including the integration of new agents into treatment paradigms and key considerations for patient education and decision-making.
- How do age restrictions for PDE4s impact your treatment decisions for pediatric patients with atopic dermatitis, and how do you address parental concerns about these options?
- Roflumilast is also approved for psoriasis and seborrheic dermatitis. Please comment on the benefits of having one treatment option for multiple conditions when managing patients with overlapping inflammatory dermatologic issues.
- In your opinion, is there an opportunity to simplify treatment with one PDE4 inhibitor for these inflammatory skin diseases?
- What are the current guidelines for using topical corticosteroids in atopic dermatitis, and how might the availability of PDE4 inhibitors impact these guidelines? [AAAAI/ACAAI, 2023][Eichenfield, 2014]
- Looking ahead, what are your thoughts regarding the future for topical PDE4 inhibitors in dermatology?
- Are you aware of emerging treatments or novel formulations on the horizon that could further change the landscape?
- How do you integrate new agents like roflumilast into existing treatment paradigms? What factors influence your decision to incorporate newer treatments over well-established options?
- When discussing topical PDE4 inhibitors with patients, what are your key considerations?
- How do you guide them through the decision-making process, and what key points do you emphasize in patient education?
Related Videos
Related Content
